HG6 Stock Overview
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for HG6 from our risk checks.
Mayne Pharma Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$4.26 |
| 52 Week High | AU$4.36 |
| 52 Week Low | AU$1.63 |
| Beta | 1.32 |
| 1 Month Change | 4.41% |
| 3 Month Change | 33.96% |
| 1 Year Change | 76.03% |
| 3 Year Change | -16.80% |
| 5 Year Change | -50.69% |
| Change since IPO | -42.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| HG6 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 7.0% | 3.2% | 1.7% |
| 1Y | 76.0% | -28.2% | 2.3% |
Return vs Industry: HG6 exceeded the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: HG6 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| HG6 volatility | |
|---|---|
| HG6 Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HG6's share price has been volatile over the past 3 months.
Volatility Over Time: HG6's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Shawn O’Brien | www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Mayne Pharma Group Limited Fundamentals Summary
| HG6 fundamental statistics | |
|---|---|
| Market cap | €349.99m |
| Earnings (TTM) | -€166.56m |
| Revenue (TTM) | €193.95m |
1.8x
P/S Ratio-2.1x
P/E RatioIs HG6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HG6 income statement (TTM) | |
|---|---|
| Revenue | AU$319.28m |
| Cost of Revenue | AU$145.07m |
| Gross Profit | AU$174.21m |
| Other Expenses | AU$448.39m |
| Earnings | -AU$274.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -3.38 |
| Gross Margin | 54.56% |
| Net Profit Margin | -85.87% |
| Debt/Equity Ratio | 5.5% |
How did HG6 perform over the long term?
See historical performance and comparison